Game-changing potential for Abrysvo and Beyfortus in pediatric RSV sec

Photo of author


Game-changing potential for Abrysvo and Beyfortus in pediatric RSV sector

US pharma giant Pfizer’s (NYSE: PFE) respiratory syncytial virus
vaccine Abrysvo (RSVpreF) earlier this month received US Food
and Drug Administration (FDA) authorization for the prevention of
lower respiratory tract disease (LRTD) and severe LRTD caused by
RSV in infants from birth up to six months of age by active
immunization of pregnant individuals at 32-36 weeks gestation.

Also, a few weeks ago, UK major AstraZeneca (LSE: AZN) and

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.


Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

Leave a comment